TEST:

PD-L1 IHC 22C3 pharmDx

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay https://t.co/n65VoUKPIS No major genomic differences in TNBC according to PDL1 status (CPS). The biology behind PD-L1 expression is still obscure! ()

OVERVIEW OF PEMBROLIZUMAB IN mTNBC ~ 1/5 pts w TNBC: PD-L1+ Pembro❌PD-1/PD-L1 pathway (specifically ❌PD-1) In 2020 FDA approved pembro + chemo for locally recurrent unresectable or #mTNBC that is PD-L1+ (CPS >10) Approved companion diagnostic test = PD-L1 IHC 22C3 ()

#tnbc Guidelines also recommend PD-L1 testing tumor & immune cells → identify candidates for immune checkpoint inhibitor (ICI) therapy FDA-approved companion diagnostic = PD-L1 IHC 22C3 pharmDx assay PD-L1+ = combined positive score (CPS) >10 ()

The #OncoAlertTopTweet 🚨 Day 2⃣ #ESMO22 Tweet @DrChoueiri 🇺🇸 PD-L1 antibodies for testing matter! @drenriquegrande 🇪🇸looking at a study in adjuvant bladder cancer: SP142 vs 22C3 Best, @weoncologists ()

We went through this in TNBC- for Atezo SP142 is the best test.. 22 C3 captures more patients . Only 1% was SP142+ and 22C3 - (@RenoHemonc)

PD-L1 antibodies for testing matter! Here with @drenriquegrande looking at a study in adjuvant bladder cancer: SP142 vs 22C3 @myESMO #ESMO22 @OncoAlert (@DrChoueiri)

Intriguing data @sundar__raghav, looking forward to seeing the presentation at #ASCO22. In my recent experience 22C3 CPS testing in #stomachcancer has become more difficult to come by, no personal experience with 28-8 CPS. ()

"CPS vs TPS, 22C3 vs 28-8, squamous vs adenocarcinoma, 0 vs 1-4 vs 1-9 vs 10 or more, primary vs metastatic site, Asian vs rest of world, esophageal vs GEJ vs gastric. Immunotherapy is the most difficult area in all of oncology in 2022. Great session. #GI22 🤯" (@TomSemrad)

Another “gee whiz” moment for immunotherapy: FDA approves an uncommonly used PD-L1 assay (SP263) as CDx for Adjuvant Atezolizumab in Stage II-IIIA NSCLC (IMpower010 trial) where SP142 used for eligibility. Yet most PD-L1 in USA is Dako22c3 & will remain so https://t.co/4rKEFKn0VF (@drgandara)

Landmark approval of atezolizumab in adjuvant NSCLC. Couple practical clinical points to consider-1) While Ventana SP263 tumor cell (TC) is how study was done, many centers utilize DAKO 22C3 (from KN24 days). Both these assays are congruent by Blueprint https://t.co/BIO7ewrSiF (@PatelOncology)

This is from @hoperugo recent talk comparing 22C3 CPS 10 to SP142. I suppose the 10% of TnBC patients that are SP142+ and CPS10 negative are now out of an immunotherapy option. #bcsm https://t.co/xfyV61kzhi (@drsarahsam)

With recent shocks in the TNBC IO field, it’s a good time to re-check this great analysis by @hoperugo & al 👉22C3+ much more common than SP142+ 👉by using 22C3 CPS>10 threshold, low concordance was noted with SP142 (22% SP142+ patients are missed) #bcsm https://t.co/aAKFsgUi1T (@PTarantinoMD)

Dealing now with a pt with resected pStage II pN1 lung adenocarcinoma mets recurrence 3 months 👀🙄s/p adjuvant cis/pem chemo completion. KEAP1, STK11+ PD-L1 50%(22C3), TMB high. Also BAP1 and SMARCA4+. Always Anticipate the Bad Actors in Neoadj and Adj therapy in NSCLC. #LCSM (@PatrickCMa1)

If adjuvant atezo becomes SOC for PDL1 >=1% NSCLC patients, what do we do about the assay? We (and I think most places) use Dako 22C3 for PDL1 IHC, would you feel comfortable treating based on that assay versus needing SP263? #ASCO21 #LCSM (@n8pennell)

PD-L1+ vs. PD-L1- #urothelialcarcinoma by Dako 22C3-TP53, RB1, APOBEC genomic alterations (GA), TMB-high in PD-L1+; FGFR3, MTAP GA in PD-L1- study by @FoundationATCG @OncJournal-https://t.co/WuRIbpHdlv @practiceupdate (@sonpavde)

Should be a nice AI project than pathologists wasting time bean counting. All 3 scores can be reported and oncologist can chose the appropriate one depending on indication. TPS for lung , IC/ SP142 for TNBC , CPS/22C3 for GI, Bladder.. (@RenoHemonc)

M/80y Smoker PS1 Stg 4 Lung Ca PD Ca with sarcomatoid hist. Pd-L1 (22C3) - 50% NGS - Palb2 VAF - 48.8% Rx - Pembro alone IO + Olaparib IO + Platinum Ipi+ Nivo Any other ? @geoff_oxnard @LeciaSequist @StephenVLiu @PatelOncology @Jbauml @DrSteveMartin @UmutDisel (@oncologician)

#WCLC20 Study design shown here - included PDL1+ by Dako 22C3 and stratified by high vs low. As we learned at #ASCO20, addition of tiragolumab increased RR (37% vs 21%), especially in PDL1 high (66% vs 24%). #LCSM (@StephenVLiu)

KEYNOTE-355 in @TheLancet Chemo-pembrolizumab vs. chemo-placebo for metastatic #TNBC: -Benefit for pembro among PDL1 high (CPS>=10 using 22C3) Javier Cortes, Dave Cescon @hoperugo @LoiSher et al https://t.co/KHQNqN3bsk @OncoAlert (@StoverLab)

Need to use the testing platform that matches the drug, they ARE NOT the same. 🧩 Atezo needs SP-142 🧩 Pembro needs 22C3 🔐 Aka, I will order both to see who may be eligible for each drug, they do not completely overlap. @OncoAlert #SABCS20 #bcsm (@ErikaHamilton9)

@JenniferLitton reviews #immuno in #TNBC 📍IMpassion130 shows benefit for PD-L1 IC+ TNBC, OS improved by 7 months 📍anatomical variance in + testing (liver least likely +) 📍SP142 does not correlate with 22C3 for atezo benefit #SABCS20 @OncoAlert #bcsm (@ErikaHamilton9)

The clinic value of PD-L1 positivity in bladder cancer depends on the antibody/algorithm. IC(288) vs TC (142) vs both(22C3,264) give different results. We should no longer bunch them together as simply +ve/-ve. Instead we should be specific around the biomarker and scenario. (@tompowles1)

These led to 1) nivo 3L+ approval #GEA (Asia) 2) pembro 3L+ approval PDL1 CPS>1 22C3 #GEA (US) 3) pembro MSI-H 2L+ any solid tumor #GEC 4) pembro 2L+ CPS>10 22C3 #EsoSCC 5) nivo 2L+ approval #EsoSCC These are the approvals as of 'the glorious day' (TGD) 9/21/20 @ #ESMO2020 (@DocCatenacci)